KR20150100903A - 알부민 및 파클리탁셀의 나노입자 조성물 - Google Patents

알부민 및 파클리탁셀의 나노입자 조성물 Download PDF

Info

Publication number
KR20150100903A
KR20150100903A KR1020157020337A KR20157020337A KR20150100903A KR 20150100903 A KR20150100903 A KR 20150100903A KR 1020157020337 A KR1020157020337 A KR 1020157020337A KR 20157020337 A KR20157020337 A KR 20157020337A KR 20150100903 A KR20150100903 A KR 20150100903A
Authority
KR
South Korea
Prior art keywords
albumin
composition
paclitaxel
pharmaceutical composition
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157020337A
Other languages
English (en)
Korean (ko)
Inventor
네일 피. 데사이
Original Assignee
아브락시스 바이오사이언스, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아브락시스 바이오사이언스, 엘엘씨 filed Critical 아브락시스 바이오사이언스, 엘엘씨
Publication of KR20150100903A publication Critical patent/KR20150100903A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A61K47/48284—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020157020337A 2012-12-28 2013-12-19 알부민 및 파클리탁셀의 나노입자 조성물 Withdrawn KR20150100903A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261747123P 2012-12-28 2012-12-28
US61/747,123 2012-12-28
US13/794,705 US20140186447A1 (en) 2012-12-28 2013-03-11 Nanoparticle compositions of albumin and paclitaxel
US13/794,705 2013-03-11
PCT/US2013/076630 WO2014105644A1 (en) 2012-12-28 2013-12-19 Nanoparticle compositions of albumin and paclitaxel

Publications (1)

Publication Number Publication Date
KR20150100903A true KR20150100903A (ko) 2015-09-02

Family

ID=51017455

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157020337A Withdrawn KR20150100903A (ko) 2012-12-28 2013-12-19 알부민 및 파클리탁셀의 나노입자 조성물

Country Status (19)

Country Link
US (2) US20140186447A1 (https=)
EP (1) EP2938340A4 (https=)
JP (2) JP2016504362A (https=)
KR (1) KR20150100903A (https=)
CN (1) CN105007912A (https=)
AU (1) AU2013370955B2 (https=)
BR (1) BR112015015319A2 (https=)
CA (1) CA2896288A1 (https=)
CR (1) CR20150386A (https=)
HK (1) HK1216611A1 (https=)
IL (1) IL239593A0 (https=)
MX (1) MX2015008361A (https=)
NI (1) NI201500090A (https=)
NZ (1) NZ630912A (https=)
PH (1) PH12015501486B1 (https=)
RU (1) RU2663687C2 (https=)
SG (1) SG11201505111TA (https=)
WO (1) WO2014105644A1 (https=)
ZA (1) ZA201504762B (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103405405A (zh) 2002-12-09 2013-11-27 阿布拉西斯生物科学有限责任公司 组合物和传递药剂的方法
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
KR101420445B1 (ko) 2005-08-31 2014-07-16 아브락시스 바이오사이언스, 엘엘씨 수 난용성 제약학적 약제 및 항균제를 포함하는 조성물
EP3470071A1 (en) 2006-12-14 2019-04-17 Abraxis BioScience, LLC Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
JP5579057B2 (ja) * 2007-06-01 2014-08-27 アブラクシス バイオサイエンス， エルエルシー 再発性癌の処置のための方法および組成物
HRP20192259T1 (hr) 2009-04-15 2020-03-06 Abraxis Bioscience, Llc Pripravci nanočestica bez priona i metode njihove proizvodnje
CA3051495A1 (en) 2010-03-26 2011-09-29 Abraxis Bioscience, Llc Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma
NZ717490A (en) 2010-03-29 2017-12-22 Abraxis Bioscience Llc Methods of treating cancer
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
BR112012030909A2 (pt) 2010-06-04 2020-08-18 Abraxis Bioscience, Llc métodos de tratamento de câncer pancreático
JP6038123B2 (ja) 2011-04-28 2016-12-07 アブラクシス バイオサイエンス， エルエルシー ナノ粒子組成物の脈管内送達およびそれらの使用
PT2707030T (pt) 2011-05-09 2020-05-22 Mayo Found Medical Education & Res Tratamentos de cancro
JP6216721B2 (ja) 2011-12-14 2017-10-18 アブラクシス バイオサイエンス， エルエルシー 粒子を凍結乾燥または凍結するためのポリマー賦形剤の使用
US10413606B2 (en) 2012-10-01 2019-09-17 Mayo Foundation For Medical Education And Research Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP3698784A1 (en) 2013-03-12 2020-08-26 Abraxis BioScience, LLC Methods of treating lung cancer
EP2968191B1 (en) 2013-03-14 2021-06-16 Abraxis BioScience, LLC Methods of treating bladder cancer
JP6387400B2 (ja) 2013-05-30 2018-09-05 ナノビオティックスＮａｎｏｂｉｏｔｉｘ 医薬組成物、その製造および使用
US20160250351A1 (en) 2014-06-13 2016-09-01 Mayo Foundation For Medical Education And Research Treating Lymphomas
EP3834889A1 (en) 2014-06-16 2021-06-16 Mayo Foundation for Medical Education and Research Treating myelomas
CN104224750A (zh) * 2014-09-17 2014-12-24 四川大学 一种注射用卡巴他赛白蛋白纳米粒制剂及其制备方法
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
KR102666251B1 (ko) 2014-11-25 2024-05-27 큐라디즘 약학적 조성물, 이의 제조 및 용도
ES2951598T3 (es) 2014-11-25 2023-10-23 Curadigm Sas Composición farmacéutica que combina al menos dos nanopartículas distintas y un compuesto farmacéutico, preparación y usos de los mismos
WO2016083331A1 (en) 2014-11-25 2016-06-02 Nanobiotix Pharmaceutical composition, preparation and uses thereof
DK3223796T3 (da) 2014-11-25 2021-09-27 Curadigm Sas Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
US10527604B1 (en) * 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
MA43100A (fr) 2015-05-28 2018-09-05 Nanobiotix Nanoparticules à utiliser en tant que vaccin thérapeutique
PL3998069T3 (pl) 2015-06-29 2025-03-31 Abraxis Bioscience, Llc Nanocząsteczki zawierające syrolimus i albuminę do zastosowania w leczeniu nowotworów z komórek nabłonkowatych
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
WO2017139698A1 (en) 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
US11305020B2 (en) 2016-03-21 2022-04-19 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
EP3432928A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
CN109890419A (zh) 2016-09-01 2019-06-14 梅约医学教育与研究基金会 用于治疗癌症的载体-pd-l1结合剂组合物
CA3035377A1 (en) 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Nanoparticle compositions for targeting t-cell cancers
WO2018048816A1 (en) 2016-09-06 2018-03-15 Mayo Foundation For Medical Education And Research Methods of treating pd-l1 expressing cancer
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
EP3509643A1 (en) 2016-09-06 2019-07-17 Mayo Foundation for Medical Education and Research Paclitaxel-albumin-binding agent compositions and methods for using and making the same
CN106420665B (zh) * 2016-10-28 2019-04-16 浙江省林业科学研究院 一种包裹紫杉烷类药物的白蛋白纳米颗粒载体的制备方法
KR20250057947A (ko) 2017-10-03 2025-04-29 크리티테크, 인크. 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달
IL277402B1 (en) 2018-03-20 2026-04-01 Abraxis Bioscience Llc Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin
US20220401374A1 (en) * 2019-09-13 2022-12-22 Purdue Research Foundation Compositions and methods for cancer treatment by enhancing antitumor immunity using tannic acid-based nanocapsules
JP7832108B2 (ja) * 2019-10-28 2026-03-17 アブラクシス バイオサイエンス， エルエルシー アルブミンおよびラパマイシンの医薬組成物
BR112022009018A2 (pt) * 2019-11-11 2022-10-11 Abraxis Bioscience Llc Biomarcadores para composições de nanopartícula
US20230074885A1 (en) * 2020-02-05 2023-03-09 The Johns Hopkins University Bortezomib-loaded nanoparticles
US20240148918A1 (en) * 2021-03-05 2024-05-09 Board Of Regents, The University Of Texas System Loading of Alginate Microspheres
KR102526793B1 (ko) * 2021-11-03 2023-04-28 주식회사 에스엔바이오사이언스 입도분포 유지 안정성이 개선된 알부민 결합 탁산 나노입자 제조방법
WO2024118542A1 (en) * 2022-11-28 2024-06-06 Takeda Vaccines, Inc. A method for the quantitative determination of human serum albumin monomer in virus-containing pharmaceutical compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728553A (en) * 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
WO2000006152A1 (en) * 1998-07-30 2000-02-10 Novopharm Biotech, Inc. Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin
JP4798832B2 (ja) * 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 ヒト血清アルブミン多量体の除去方法
PL2470173T3 (pl) * 2009-08-25 2016-11-30 Leczenie skojarzone nanocząstkowymi kompozycjami taksanu i inhibitorów hedgehog
CA3051495A1 (en) * 2010-03-26 2011-09-29 Abraxis Bioscience, Llc Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma
WO2012092712A1 (zh) * 2011-01-07 2012-07-12 无锡圆容生物医药股份有限公司 一种含有重组人血白蛋白的纳米颗粒冷冻干燥粉末制剂
CN102078306A (zh) * 2011-01-11 2011-06-01 无锡圆容生物医药股份有限公司 一种含有重组人血白蛋白的紫杉醇纳米颗粒冷冻干燥制剂

Also Published As

Publication number Publication date
NI201500090A (es) 2015-12-22
US20190192477A1 (en) 2019-06-27
RU2663687C2 (ru) 2018-08-08
CA2896288A1 (en) 2014-07-03
HK1216611A1 (zh) 2016-11-25
WO2014105644A1 (en) 2014-07-03
EP2938340A4 (en) 2016-08-03
BR112015015319A2 (pt) 2017-07-11
AU2013370955B2 (en) 2018-12-06
CR20150386A (es) 2015-10-07
AU2013370955A1 (en) 2015-07-16
PH12015501486B1 (en) 2020-12-16
US20140186447A1 (en) 2014-07-03
PH12015501486A1 (en) 2015-09-21
CN105007912A (zh) 2015-10-28
RU2015131141A (ru) 2017-02-03
NZ630912A (en) 2017-05-26
JP2016504362A (ja) 2016-02-12
JP2018087241A (ja) 2018-06-07
EP2938340A1 (en) 2015-11-04
MX2015008361A (es) 2016-03-11
ZA201504762B (en) 2016-10-26
IL239593A0 (en) 2015-08-31
SG11201505111TA (en) 2015-07-30

Similar Documents

Publication Publication Date Title
AU2013370955B2 (en) Nanoparticle compositions of albumin and paclitaxel
JP6257324B2 (ja) 膵臓がんの処置方法
KR101943230B1 (ko) 항암제로서 라파마이신 및 알부민을 포함하는 나노입자
CN105120859B (zh) 治疗黑素瘤的方法
US11166914B2 (en) Tumor therapeutic agent and kit containing gemcitabine liposome composition
CN101170995B (zh) 新颖的脂质体组合物
CN107405328B (zh) 多西他赛白蛋白纳米粒药物组合物及其制备方法及应用
KR20170101925A (ko) 병용 요법
ES2984148T3 (es) Medicamento de combinación que contiene una composición liposómica que encapsula un fármaco y un inhibidor de punto de control inmunitario
CN109771663B (zh) 一种酸响应性抗癌纳米药物的制备及应用
CN109562073B (zh) 白蛋白药物组合物及其制备方法
WO2023208009A1 (zh) 一种速溶型纳米粒子组合物及其制备方法
CN115400115B (zh) 多西他赛白蛋白组合物和免疫检查点抑制剂的组合及用途
AU2018328532A1 (en) Pharmaceutical composition of docetaxel conjugate and preparation method
HK40102079A (zh) 一种速溶型纳米粒子组合物及其制备方法
WO2021213327A1 (zh) 包含7-乙基-10-羟基喜树碱的组合物及其制备方法和用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000